REPLIMUNE GROUP, INC. Total Liabilities and Equity
REPLIMUNE GROUP, INC. (REPL) had Total Liabilities and Equity of $252.45 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-14
- 2026-06-30: Liabilities and Equity $252.45M.
- 2026-03-31: Liabilities and Equity $332.39M.
- 2025-12-31: Liabilities and Equity $333.59M.
- 2025-09-30: Liabilities and Equity $389.45M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $252.45M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $332.39M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $333.59M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $389.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $469.51M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $551.33M 10-K · filed 2026-06-29 |
| 2024-12-31 | $603.63M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $498.20M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $534.97M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $487.72M 10-K · filed 2025-05-22 |
| 2023-12-31 | $532.93M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $562.40M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $603.89M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $646.59M 10-K · filed 2024-05-16 |
| 2022-12-31 | $678.55M 10-Q · filed 2023-02-09 |
| 2022-09-30 | $436.10M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $459.43M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $461.19M 10-K · filed 2023-05-18 |
| 2021-12-31 | $485.28M 10-Q · filed 2022-02-03 |
| 2021-09-30 | $503.46M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $523.72M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $543.10M 10-K · filed 2022-05-19 |
| 2020-12-31 | $559.20M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $314.24M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $329.58M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $234.10M 10-K · filed 2021-05-20 |
| 2019-12-31 | $250.42M 10-Q · filed 2020-02-13 |
| 2019-09-30 | $151.44M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $143.54M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $154.33M 10-K · filed 2020-06-03 |
| 2018-12-31 | $152.19M 10-Q · filed 2019-02-14 |
| 2018-09-30 | $153.82M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $59.29M 10-Q · filed 2018-08-30 |
| 2018-03-31 | $65.15M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |